Skip to main content

EDITORIAL article

Front. Bioeng. Biotechnol., 19 April 2024
Sec. Nanobiotechnology
This article is part of the Research Topic New Marketable Discoveries in Nanobiotechnology View all 8 articles

Editorial: New marketable discoveries in nanobiotechnology

  • 1Research Group Structural Biology Brussels, Alliance Research Group VUB-UGhent NanoMicrobiology (NAMI), Vrije Universiteit Brussel (VUB), Brussels, Belgium
  • 2International Joint Research Group VUB-EPFL BioNanotechnology & NanoMedicine (NANO), Brussels, Switzerland
  • 3Laboratory of Biological Electron Microscopy, Ecole Polytechnique Fédérale de Lausanne (EPFL) and University of Lausanne, Lausanne, Switzerland
  • 4Centre Universitaire Romand de Médecine Légale, UFAM, Université de Lausanne, Lausanne, Switzerland

Editorial on the Research Topic
New marketable discoveries in nanobiotechnology

With the potential to advance the current scientific landscape, nanobiotechnology represents a flourishing area of research worldwide. With the increasingly innovative approaches being worked on by scientists, we foresee that this will significantly contribute to next-generation development and application in this field. The Research Topic aims to collect and disseminate new marketable discoveries in nanobiotechnology science worldwide to a global audience, promoting its development with the evolutionary concepts and ideas from laboratories across the globe.

Deng et al. reviewed the present state of nanotechnology in orthopedic surgery, its applications as well as possible future developments. In recent years, numerous medical fields have been revolutionized by the advent of nanotechnology. The authors reviewed comprehensively the recent developments of nanotechnology in the field of orthopedic surgery. More specifically these discussed the impact of nanotechnology in joint replacements, drug delivery systems, orthopedic oncology, chondral and osseous deformities, implant material, as well as applications for imaging and the developments of novel sensors for diagnosis.

Freitas et al. evaluated the antimicrobial and wound-healing potential of naphthoquinones encapsulated in nanochitosan. The use of chitosan to encapsulate pharmacologically active compounds has many advantages such as its biocompatibility, biodegradability, and low cost. The coumpounds naphthoquinones 3- chloromethylene-menadione (NQ1) and 2,3-dichloro-1,4-naphthoquinone (NQ2) were nanoencapsulated into chitosan (CNP) by the ionotropic gelatinization technique and evaluated for their antimicrobial and wound healing activities. Both encapsulated compounds retained their naphthoquinone antimicrobial activity against Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes and Pseudomonas aeruginosa. Only CNP-NQ1 displayed low toxicity for safe use in human tissues. Scratch assays suggested successfully wound healing properties of the compound that prevent bacterial contamination, and accelerate dermal tissue recovery.

Alogla reviewed how antioxidant delivery for therapeutic strategies can be enhanced by using 3D printing. Incorporating antioxidants into 3D-printed matrices enables controlled release and localized delivery, improving efficacy while minimizing side effects. Encapsulation techniques such as direct mixing, coating, and encapsulation are discussed. The author also reviewed various 3D printing methods and materials, printing parameters, as well as post-processing methods to influence antioxidant release kinetics and stability. Applications include wound healing, tissue regeneration, 3D-printed bone scaffolds, drug delivery, and foods with 3D-printed antioxidants.

Nagai et al. developed orally disintegrating tablets containing famotidine nanoparticles that provide high intestinal absorbability. Famotidine (FAM) nanoparticles were used to enhance oral bioavailability. Dispersions containing FAM nanoparticles with a particle size of approximately 50–220 nm were produced by the bead-milling treatment and included in an orally disintegrating tablet formulation. In vivo evaluation in rats showed improved mucosal permeability and oral bioavailability.

Kweku et al. developed a machine-learning method for the classification of the state of living organisms’ oscillations as detected by Atomic Force Microscopy (AFM)-based nanomotion detectors. Such devices provide rapid antibiotic sensitivity tests that are crucial for the treatment of bacterial infections. The interpretation of the data delivered by such devices is not trivial and in this contribution, the authors implemented a machine-learning algorithm that classifies bacterial responses to antibiotics. The efficiency of the method was demonstrated by classifying living Bordetella pertussis bacteria in the virulent or avirulence phase, and dead bacteria, based on their cellular nanomotion signal. The method offers significant advantages over current approaches, as it is significantly faster and more accurate.

Arai et al. developed a thyroid-stimulating hormone assay system for a benchtop digital ELISA desktop analyzer. Regular checkups for thyroid-stimulating hormone (TSH) levels are essential for the diagnosis of thyroid disease. By utilizing the ultrasensitivity of the digital immunoassay (d-IA) based on functionalized magnetic beads, the authors were able to use a sample volume of as little as 5 µL for each assay. The correlation between serum and plasma levels indicated a good agreement and a sensitivity of 0.002280 μIU/mL was obtained.

Ma et al. developed a high-throughput screening system based on micropillars for three-dimensional engineered cardiac tissues (3D ECTs). To balance the inherent tradeoff among imaging resolution, field of view, and speed, an innovative mosaic imaging system was designed, built, and validated to sense the contractile force of 3D ECTs in a 96-well plate setup. The system performance was validated for up to 3 weeks. The developed method significantly reduces the cost, time, and labor needed for preclinical cardiotoxicity assay.

Author contributions

RW: Writing–original draft, Writing–review and editing. SK: Writing–original draft, Writing–review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Belgian Federal Science Policy Office (Belspo) and the European Space Agency (ESA), grant number PRODEX Flumias Nanomotion; FWO, grant number I002620; FWO-SNSF, grant number 310030L_197946; SK is supported by SNSF grants CRSII5_173863.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: orthopedic surgery, nanochitosan encapsulation, 3D printing, fomatidine nanoparticles, nanomotion detection, thryroid-stimulating hormone assay, cardiac tissue contractile force, machine-learning (ML)

Citation: Willaert RG and Kasas S (2024) Editorial: New marketable discoveries in nanobiotechnology. Front. Bioeng. Biotechnol. 12:1412587. doi: 10.3389/fbioe.2024.1412587

Received: 05 April 2024; Accepted: 11 April 2024;
Published: 19 April 2024.

Edited and reviewed by:

Gianni Ciofani, Italian Institute of Technology (IIT), Italy

Copyright © 2024 Willaert and Kasas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ronnie G. Willaert, ronnie.willaert@vub.ac.be

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.